File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Progression-free survival among progressed non-small-cell lung cancer with T790M mutation as guided by liquid versus tissue re-biopsy
Title | Progression-free survival among progressed non-small-cell lung cancer with T790M mutation as guided by liquid versus tissue re-biopsy |
---|---|
Authors | |
Issue Date | 2019 |
Publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ |
Citation | 24th Medical Research Conference, Department of Medicine, the University of Hong Kong, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, 2019, v. 25 n. 1, Suppl. 1, p. 25, abstract no. 33 How to Cite? |
Abstract | Background: Osimertinib has been approved by the United States Food and Drug Administration for nonsmall-cell lung carcinoma (NSCLC) harbouring acquired T790M mutation that have progressed while on other epidermal growth factor inhibitor (EGFR)–inhibiting therapy. We compared the progression-free survival (PFS) of patients whose T790M mutation was identified by liquid biopsy with those identified by tissue sampling.
Methods: This was a retrospective single-centre cohort study conducted in Queen Mary Hospital, Hong Kong. The study included 139 Chinese patients with advanced NSCLC who had disease progression after first-line EGFR tyrosine kinase inhibitor and received osimertinib upon detection of T790M mutation, either by liquid biopsy (by identification of circulating tumour DNA) or tissue re-biopsy. The primary endpoint was PFS.
Results: Patients with EGFR T790M mutation detected by tissue sampling (n=37) had significantly better PFS than those detected by peripheral blood liquid biopsy (n=102) [median 380 vs 213 days, hazard ratio=0.576, 95% confidence interval=0.359-0.925, P=0.021]. A small subgroup with positive liquid biopsy but concomitant negative tissue result (n=6) had the lowest PFS among the different cohorts (median PFS=57 days).
Conclusions: Tissue re-biopsy for T790M mutation is preferred for patients who have NSCLC that progressed after first-line tyrosine kinase inhibitor. For cases that only have confirmatory liquid biopsy results, clinicians should inform their patient that the expected PFS may be significantly shorter than those previously reported in literature. |
Persistent Identifier | http://hdl.handle.net/10722/275316 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.261 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwok, WC | - |
dc.contributor.author | Ho, JCM | - |
dc.contributor.author | Lam, CLD | - |
dc.contributor.author | Lui, MSM | - |
dc.contributor.author | Ip, MSM | - |
dc.contributor.author | Tam, CCT | - |
dc.date.accessioned | 2019-09-10T02:40:05Z | - |
dc.date.available | 2019-09-10T02:40:05Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | 24th Medical Research Conference, Department of Medicine, the University of Hong Kong, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, 2019, v. 25 n. 1, Suppl. 1, p. 25, abstract no. 33 | - |
dc.identifier.issn | 1024-2708 | - |
dc.identifier.uri | http://hdl.handle.net/10722/275316 | - |
dc.description.abstract | Background: Osimertinib has been approved by the United States Food and Drug Administration for nonsmall-cell lung carcinoma (NSCLC) harbouring acquired T790M mutation that have progressed while on other epidermal growth factor inhibitor (EGFR)–inhibiting therapy. We compared the progression-free survival (PFS) of patients whose T790M mutation was identified by liquid biopsy with those identified by tissue sampling. Methods: This was a retrospective single-centre cohort study conducted in Queen Mary Hospital, Hong Kong. The study included 139 Chinese patients with advanced NSCLC who had disease progression after first-line EGFR tyrosine kinase inhibitor and received osimertinib upon detection of T790M mutation, either by liquid biopsy (by identification of circulating tumour DNA) or tissue re-biopsy. The primary endpoint was PFS. Results: Patients with EGFR T790M mutation detected by tissue sampling (n=37) had significantly better PFS than those detected by peripheral blood liquid biopsy (n=102) [median 380 vs 213 days, hazard ratio=0.576, 95% confidence interval=0.359-0.925, P=0.021]. A small subgroup with positive liquid biopsy but concomitant negative tissue result (n=6) had the lowest PFS among the different cohorts (median PFS=57 days). Conclusions: Tissue re-biopsy for T790M mutation is preferred for patients who have NSCLC that progressed after first-line tyrosine kinase inhibitor. For cases that only have confirmatory liquid biopsy results, clinicians should inform their patient that the expected PFS may be significantly shorter than those previously reported in literature. | - |
dc.language | eng | - |
dc.publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ | - |
dc.relation.ispartof | 24th Medical Research Conference, Department of Medicine, the University of Hong Kong | - |
dc.relation.ispartof | Hong Kong Medical Journal | - |
dc.rights | Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press. | - |
dc.title | Progression-free survival among progressed non-small-cell lung cancer with T790M mutation as guided by liquid versus tissue re-biopsy | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Ho, JCM: jhocm@hku.hk | - |
dc.identifier.email | Lam, CLD: dcllam@hku.hk | - |
dc.identifier.email | Lui, MSM: drmslui@hku.hk | - |
dc.identifier.email | Ip, MSM: msmip@hku.hk | - |
dc.identifier.email | Tam, CCT: tamcct@hku.hk | - |
dc.identifier.authority | Ho, JCM=rp00258 | - |
dc.identifier.authority | Lam, CLD=rp01345 | - |
dc.identifier.authority | Ip, MSM=rp00347 | - |
dc.identifier.hkuros | 303434 | - |
dc.identifier.volume | 25 | - |
dc.identifier.issue | 1, Suppl. 1 | - |
dc.identifier.spage | 25, abstract no. 33 | - |
dc.identifier.epage | 25, abstract no. 33 | - |
dc.publisher.place | Hong Kong | - |
dc.identifier.issnl | 1024-2708 | - |